Fortress Biotech (FBIO.P) Stock Overview
Operates as a biopharmaceutical company in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
FBIO.P Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Fortress Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.11 |
| 52 Week High | US$21.43 |
| 52 Week Low | US$6.27 |
| Beta | 1.19 |
| 1 Month Change | -0.11% |
| 3 Month Change | -9.72% |
| 1 Year Change | 113.94% |
| 3 Year Change | 47.12% |
| 5 Year Change | -28.91% |
| Change since IPO | -25.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| FBIO.P | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.6% | -3.1% | -1.6% |
| 1Y | 113.9% | 37.2% | 12.1% |
Return vs Industry: FBIO.P exceeded the US Biotechs industry which returned 37.2% over the past year.
Return vs Market: FBIO.P exceeded the US Market which returned 12.1% over the past year.
Price Volatility
| FBIO.P volatility | |
|---|---|
| FBIO.P Average Weekly Movement | 2.7% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: FBIO.P has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FBIO.P's weekly volatility has decreased from 8% to 3% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 78 | Lindsay Rosenwald | www.fortressbiotech.com |
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia.
Fortress Biotech, Inc. Fundamentals Summary
| FBIO.P fundamental statistics | |
|---|---|
| Market cap | US$83.04m |
| Earnings (TTM) | US$103.37m |
| Revenue (TTM) | US$68.47m |
Is FBIO.P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FBIO.P income statement (TTM) | |
|---|---|
| Revenue | US$68.47m |
| Cost of Revenue | US$25.14m |
| Gross Profit | US$43.32m |
| Other Expenses | -US$60.04m |
| Earnings | US$103.37m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.10 |
| Gross Margin | 63.28% |
| Net Profit Margin | 150.98% |
| Debt/Equity Ratio | 19.2% |
How did FBIO.P perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/16 23:18 |
| End of Day Share Price | 2026/09/16 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fortress Biotech, Inc. is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Stephen V. Byrne | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |